Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes C van der Mijn

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 3, 2014
Predictive biomarkers in renal cell cancer: insights in drug resistance mechanismsJohannes C van der Mijn, James W Mier, Henk J Broxterman, et al.
Molecular Imaging|March 16, 2012
Codon-optimized Luciola italica luciferase variants for mammalian gene expression in culture and in vivoCasey A Maguire, Johannes C van der Mijn, Marja H Degeling, et al.
Cancer & Metabolism|July 16, 2016
Novel drugs that target the metabolic reprogramming in renal cell cancerJohannes C van der Mijn, David J Panka, Andrew K Geissler, et al.
The Oncologist|September 5, 2014
Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignanciesMariette Labots, Lisette M Schütte, Johannes C van der Mijn, et al.
Case Reports in Oncology|March 2, 2012
Irinotecan-induced dysarthriaAlbertine J Dressel, Johannes C van der Mijn, Ijke J Aalders, et al.
Case Reports in Oncology|March 9, 2018
Lactic Acidosis in Prostate Cancer: Consider the Warburg EffectJohannes C van der Mijn, Mathijs J Kuiper, Carl E H Siegert, et al.
Journal of Proteomics|April 19, 2015
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomicsJohannes C van der Mijn, Mariette Labots, Sander R Piersma, et al.
Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.
Molecular Carcinogenesis|June 21, 2022
Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR)Johannes C van der Mijn, Qiuying Chen, Kristian B Laursen, et al.
Experimental & Molecular Medicine|December 17, 2016
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancerMariette Labots, Kristy J Gotink, Henk Dekker, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 3, 2014
Predictive biomarkers in renal cell cancer: insights in drug resistance mechanismsJohannes C van der Mijn, James W Mier, Henk J Broxterman, et al.
Molecular Imaging|March 16, 2012
Codon-optimized Luciola italica luciferase variants for mammalian gene expression in culture and in vivoCasey A Maguire, Johannes C van der Mijn, Marja H Degeling, et al.
Cancer & Metabolism|July 16, 2016
Novel drugs that target the metabolic reprogramming in renal cell cancerJohannes C van der Mijn, David J Panka, Andrew K Geissler, et al.
The Oncologist|September 5, 2014
Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignanciesMariette Labots, Lisette M Schütte, Johannes C van der Mijn, et al.
Case Reports in Oncology|March 2, 2012
Irinotecan-induced dysarthriaAlbertine J Dressel, Johannes C van der Mijn, Ijke J Aalders, et al.
Case Reports in Oncology|March 9, 2018
Lactic Acidosis in Prostate Cancer: Consider the Warburg EffectJohannes C van der Mijn, Mathijs J Kuiper, Carl E H Siegert, et al.
Journal of Proteomics|April 19, 2015
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomicsJohannes C van der Mijn, Mariette Labots, Sander R Piersma, et al.
Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.
Molecular Carcinogenesis|June 21, 2022
Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR)Johannes C van der Mijn, Qiuying Chen, Kristian B Laursen, et al.
Experimental & Molecular Medicine|December 17, 2016
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancerMariette Labots, Kristy J Gotink, Henk Dekker, et al.
Pageof 3